Laurus Labs to manufacture Molnupiravir, oral COVID-19 medication in association with MPP

21 Jan 2022 , 12:44 PM

Laurus Labs Ltd. has signed an agreement with MPP (Medicine Patient Pool) for the manufacturing of the oral COVID-19 antiviral medication Molnupiravir.

The company is happy to sign an agreement to manufacture the oral Covid-19 antiviral medication, being an urgent need of the hour, this is one of the most crucial steps towards fighting the pandemic and the company is happy to be contributing to the mission, stated the company in its regulatory filing.

Laurus Labs is a fully integrated pharmaceutical and biotechnology company, with a leadership position in generic Active Pharmaceutical Ingredients (APIs) and a major focus on anti-retroviral, Hepatitis C, and oncology drugs.

The company also develops and manufactures oral solid formulations, provides contract research and manufacturing services (CRAMS) to Global pharma companies, and produces specialty ingredients for nutraceuticals, dietary supplements, and cosmeceuticals. The company is highly passionate about advanced chemistry skills.